Evidence map›Paper›PMID 40099133›Full record

ArticleBMJ public health2025

Key factors determining the development of SARS-CoV-2 testing strategies in EU countries: a mixed-methods study.

L S Kengne Kamga, A C G Voordouw, M C De Vries, A Timen, M P G Koopmans

Abstract read
In one paragraph

Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

L S Kengne KamgaCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.ORCID 0000-0003-4615-4606
A C G VoordouwCenter for Infectious Disease Research, Diagnostics and Laboratory Surveillance, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
M C De VriesCenter for Infectious Disease Research, Diagnostics and Laboratory Surveillance, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
A TimenCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
M P G KoopmansDepartment of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The WHO and the European Center for Disease Prevention and Control (ECDC) advocated for extensive testing as a crucial pillar in managing the COVID-19 pandemic. Yet, public health emergency responses varied across European countries. In particular, there were differences in the national laboratory capacities and diagnostic testing strategies. This study was conducted during the pandemic to identify the key factors in developing national, SARS-CoV-2 testing strategies across a selection of European countries. Methods: A mixed-methods study, comprising an interview phase and a survey phase, was performed. First, laboratory, policy-making and/or public health experts from different European countries were interviewed between 8 January 2021 and 19 March 2021, to review the development and implementation of national testing strategies.Second, a cross-sectional survey was conducted among ECDC National Focal Points (NFP) for Preparedness and Response and/or Microbiology between July and October 2022 to validate the interview findings. Results: 12 European experts were interviewed and identified the following key factors determining the development of the national SARS-COV-2 testing strategies in their countries: (1) changing testing goals over time, (2) the prevailing epidemiological situation, (3) testing capacities, (4) availability of reference laboratories, (5) supply and stockpiling of testing material, (6) availability of human resources and (7) quality management standards across laboratories. The experts interviewed stressed the important role of stockpile management, the existence of expert networks, as well as the centralisation of decision-making. Lastly, determining the actors responsible for the testing strategy and putting in place 'coordination, accountability and governance' proved to be pivotal.The survey outcome with 15 European NFPs demonstrated that the testing strategies generally changed over time to include a broader group of individuals. Furthermore, the actors 'Ministry of Health', 'Public health officials', 'National public health institutes' and 'National Expert and/or advisory groups' were selected as key players by survey respondents. Conclusions: In general, the scope of the testing strategy in European countries included in this study expanded as the pandemic progressed. This study identified key factors discussed by European experts interviewed that contributed to the development of SARS-CoV-2 testing strategies across European countries.

Indexed as

Communicable Disease ControlDisease OutbreaksPublic HealthSARS-CoV-2

Identifiers

PMID40099133
PMCPMC11911672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.